Physiologically based pharmacokinetic modeling and simulation to predict drug –drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia
ConclusionPotentially clinically relevant DDI effects with CYP3A4 inducers and moderate and strong inhibitors co-administered with ivosidenib were predicted. Considering the challenges of conducting clinical DDI studies in patients, this PBPK approach is valuable in ivosidenib DDI risk assessment and management.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Fluconazole | Ketoconazole | Leukemia | Oral Cancer | Study